Cullen/Frost Bankers’s Takeda Pharmaceutical TAK Stock Holding History

Cullen/Frost Bankers’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-137	Closed	-$1.81K	–	1468
2024 Q4	$1.81K	Buy	+137	New	+$1.88K	﹤0.01%	1156
2022 Q4	–	Sell	-903	Closed	-$12K	–	1199
2022 Q3	$12K	Buy	+903	New	+$12.6K	﹤0.01%	925
2022 Q1	–	Sell	-125	Closed	-$2K	–	1247
2021 Q4	$2K	Hold	125	–	–	﹤0.01%	1084
2021 Q3	$2K	Hold	125	–	–	﹤0.01%	1169
2021 Q2	$2K	Hold	125	–	–	﹤0.01%	1165
2021 Q1	$2K	Hold	125	–	–	﹤0.01%	1027
2020 Q4	$2K	Sell	125 -221	-64%	-$3.88K	﹤0.01%	1014
2020 Q3	$6K	Sell	346 -1,867	-84%	-$34K	﹤0.01%	958
2020 Q2	$40K	Buy	2,213 +1,917	+648%	+$34.4K	﹤0.01%	698
2020 Q1	$4K	Sell	296 -181	-38%	-$3.28K	﹤0.01%	818
2019 Q4	$9K	Sell	477 -1,889	-80%	-$36.1K	﹤0.01%	906
2019 Q3	$41K	Buy	2,366 +146	+7%	+$2.52K	﹤0.01%	598
2019 Q2	$39K	Sell	2,220 -4,062	-65%	-$73.9K	﹤0.01%	598
2019 Q1	$128K	Buy	+6,282	New	+$126K	﹤0.01%	442

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Cullen/Frost Bankers's TAK Position: Q1 2025 in Review

Cullen/Frost Bankers sold out of Takeda Pharmaceutical (TAK) in Q1 2025, closing a stake of 137 shares — an estimated $1.81K sold.

Cullen/Frost Bankers first reported a position in TAK in Q1 2019 and held it in 14 quarters. The position peaked at $128K in Q1 2019. 308 funds tracked by Wall St. Rank hold TAK as of Q1 2025.

Cullen/Frost Bankers reported no remaining Takeda Pharmaceutical position as of Q1 2025 after selling out during the quarter.
Cullen/Frost Bankers sold 137 Takeda Pharmaceutical shares in Q1 2025, an estimated $1.81K.
Cullen/Frost Bankers first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 14 quarters.
Cullen/Frost Bankers's Takeda Pharmaceutical position peaked at $128K in Q1 2019.
308 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2025.

Based on Cullen/Frost Bankers's 13F filing for Q1 2025, filed 2 May 2025.